Allogene Therapeutics’ (ALLO) “Outperform” Rating Reiterated at William Blair

William Blair reissued their outperform rating on shares of Allogene Therapeutics (NASDAQ:ALLO) in a report issued on Thursday,RTT News reports.

A number of other equities research analysts also recently weighed in on the stock. Oppenheimer started coverage on shares of Allogene Therapeutics in a research note on Thursday, August 8th. They set an “outperform” rating and a $11.00 price target for the company. Citigroup upped their target price on shares of Allogene Therapeutics from $7.00 to $8.00 and gave the company a “buy” rating in a research report on Friday, August 9th. Piper Sandler reduced their price target on Allogene Therapeutics from $11.00 to $9.00 and set an “overweight” rating on the stock in a research report on Thursday. Truist Financial reiterated a “buy” rating and issued a $14.00 price objective (down previously from $17.00) on shares of Allogene Therapeutics in a report on Friday, August 9th. Finally, HC Wainwright restated a “buy” rating and set a $9.00 target price on shares of Allogene Therapeutics in a report on Friday, November 8th. Three equities research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $9.73.

Allogene Therapeutics Trading Down 7.7 %

Shares of NASDAQ:ALLO opened at $2.27 on Thursday. Allogene Therapeutics has a 1-year low of $2.01 and a 1-year high of $5.78. The stock has a market capitalization of $475.95 million, a P/E ratio of -1.46 and a beta of 0.84. The business has a 50-day moving average price of $2.75 and a two-hundred day moving average price of $2.66.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Geode Capital Management LLC lifted its holdings in shares of Allogene Therapeutics by 14.4% during the 3rd quarter. Geode Capital Management LLC now owns 3,227,104 shares of the company’s stock valued at $9,037,000 after purchasing an additional 407,070 shares in the last quarter. Barclays PLC raised its holdings in Allogene Therapeutics by 101.5% during the 3rd quarter. Barclays PLC now owns 342,973 shares of the company’s stock worth $959,000 after buying an additional 172,745 shares during the period. MML Investors Services LLC bought a new position in Allogene Therapeutics in the third quarter valued at approximately $56,000. Zacks Investment Management acquired a new position in shares of Allogene Therapeutics in the third quarter valued at approximately $1,446,000. Finally, EP Wealth Advisors LLC increased its position in shares of Allogene Therapeutics by 125.6% during the third quarter. EP Wealth Advisors LLC now owns 24,475 shares of the company’s stock worth $69,000 after acquiring an additional 13,625 shares in the last quarter. 83.63% of the stock is owned by institutional investors and hedge funds.

Allogene Therapeutics Company Profile

Allogene Therapeutics, Inc, a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL).